BrightSpring Reports 26% Revenue Growth, Raises 2026 Guidance
BrightSpring reported Q3 2026 revenue of $4.21B, up 26.4% YoY, with net income of $101M. Adjusted EBITDA rose 42.0% to $228M. The company raised its full-year 2026 revenue and EBITDA guidance. Pharmacy Solutions and Provider Services saw significant growth, and the company completed the divestiture of its Community Living business.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide a clear catalyst for the stock, likely prompting buying interest.
Market read
BrightSpring's earnings beat and raised outlook could drive its stock higher and attract sector attention.
What to watch
Integration risks from the Amedisys and LHC acquisition could temper performance.
Background
BrightSpring Health Services reported Q3 2026 results with revenue of $4.21B, a 26% YoY increase, and raised its full-year revenue guidance to $15.9‑$16.13B and Adjusted EBITDA guidance to $850‑$860M.
Ticker impact
BrightSpring reported Q3 2026 revenue up 26% YoY and raised full-year 2026 revenue and Adjusted EBITDA guidance.
likely upside as market prices in higher revenue and EBITDA guidance
Revenue beat and guidance raise suggest improved earnings prospects and growth momentum.
Market effects
Home health and pharmacy services sector may see increased investor interest.
U.S. healthcare services market could benefit from stronger earnings outlook.
Impact largely confined to U.S. healthcare investors.
Counterpoint
Guidance may already be priced in, limiting upside potential.
Key entities
- companyBrightSpring Health Services, Inc.
U.S.-listed provider of home health and pharmacy services.
- companyAmedisys
Healthcare provider whose branch acquisition is expected to add ~$35M Adjusted EBITDA in 2026.
- companyLHC
Healthcare provider involved in the acquisition with BrightSpring.
